Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer

The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC). The quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST)...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Sherrill, B, Amonkar, M M, Stein, S, Walker, M, Geyer, C, Cameron, D
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2008
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2528149/
https://ncbi.nlm.nih.gov/pubmed/18728660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604501
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg